Fredric Manfredsson

Prof. Fredric Manfredsson

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2016 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
MBMatthew J. Benskey
Matthew J. Benskey
RPRuth G. Perez
Ruth G. Perez
FMFredric Manfredsson
Fredric Manfredsson
The aggregation of alpha synuclein (α‐syn) is a neuropathological feature that defines a spectrum of disorders collectively termed synucleinopathies, and of these, Parkinson's disease (PD) is arguably the best characterized. Aggregated α‐syn is the primary component of Lewy bodies, the defining pathological feature ofPD, while mutations or multiplications in the α‐syn gene result in familialPD. The high correlation between α‐syn burden andPDhas led to the hypothesis that α‐syn aggregation produces toxicity through a gain‐of‐function mechanism. However, α‐syn has been implicated to function in a diverse range of essential cellular processes such as the regulation of neurotransmission and response to cellular stress. As such, an alternative hypothesis with equal explanatory power is that the aggregation of α‐syn results in toxicity because of a toxic loss of necessary α‐syn function, following sequestration of functional forms α‐syn into insoluble protein aggregates. Within this review, we will provide an overview of the literature linking α‐syn toPDand the knowledge gained from current α‐syn‐based animal models ofPD. We will then interpret these data from the viewpoint of the α‐syn loss‐of‐function hypothesis and provide a potential mechanistic model by which loss of α‐syn function could result in at least some of the neurodegeneration observed inPD. By providing an alternative perspective on the etiopathogenesis ofPDand synucleinopathies, this may reveal alternative avenues of research in order to identify potential novel therapeutic targets for disease modifying strategies. image The correlation between α‐synuclein burden and Parkinson's disease pathology has led to the hypothesis that α‐synuclein aggregation produces toxicity through a gain‐of‐function mechanism. However, in this review, we discuss data supporting the alternative hypothesis that the aggregation of α‐synuclein results in toxicity because of loss of necessary α‐synuclein function at the presynaptic terminal, following sequestration of functional forms of α‐synuclein into aggregates.

3 July 2017 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
ZZZhentao Zhang
Zhentao Zhang
SKSeong Su Kang
Seong Su Kang
XLXia Liu
Xia Liu
EAEun Hee Ahn
Eun Hee Ahn
ZZZhaohui Zhang
Zhaohui Zhang
KYKeqiang Ye
Keqiang Ye

1 April 2018 in Neurobiology of Disease
Verified
Journal Article
Closed access
FMFredric Manfredsson
Fredric Manfredsson
KLKelvin C. Luk
Kelvin C. Luk
MBMatthew J. Benskey
Matthew J. Benskey
AGAysegul Gezer
Aysegul Gezer
JGJoanna Garcia
Joanna Garcia
JKJeffrey H. Kordower
Jeffrey H. Kordower

3 May 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
ZWZhi-Hao Wang
Zhi-Hao Wang
KGKe Gong
Ke Gong
XLXia Liu
Xia Liu
ZZZhentao Zhang
Zhentao Zhang
XSXiaoou Sun
Xiaoou Sun
KYKeqiang Ye
Keqiang Ye
Delta-secretase cleaves both APP and Tau to mediate the formation of amyloid plaques and neurofibrillary tangle in Alzheimer’s disease (AD). However, how aging contributes to an increase in delta-secretase expression and AD pathologies remains unclear. Here we show that a CCAAT-enhancer-binding protein (C/EBPβ), an inflammation-regulated transcription factor, acts as a key age-dependent effector elevating both delta-secretase (AEP) and inflammatory cytokines expression in mediating pathogenesis in AD mouse models. We find that C/EBPβ regulates delta-secretase transcription and protein levels in an age-dependent manner. Overexpression of C/EBPβ in young 3xTg mice increases delta-secretase and accelerates the pathological features including cognitive dysfunctions, which is abolished by inactive AEP C189S. Conversely, depletion of C/EBPβ from old 3xTg or 5XFAD mice diminishes delta-secretase and reduces AD pathologies, leading to amelioration of cognitive impairment in these AD mouse models. Thus, our findings support that C/EBPβ plays a pivotal role in AD pathogenesis via increasing delta-secretase expression.

28 June 2021 in eClinicalMedicine
Verified
Journal Article
Open access
ASAndrea Sturchio
Andrea Sturchio
ADAlok K. Dwivedi
Alok K. Dwivedi
CYChristina B. Young
Christina B. Young
TMTarja Malm
Tarja Malm
LMLuca Marsili
Luca Marsili
AEAlberto J. Espay
Alberto J. Espay
Brain amyloidosis does not invariably predict dementia. We hypothesized that high soluble 42-amino acid β amyloid (Aβ42) peptide levels are associated with normal cognition and hippocampal volume despite increasing brain amyloidosis. This cross-sectional study of 598 amyloid-positive participants in the Alzheimer's Disease Neuroimaging Initiative cohort examined whether levels of soluble Aβ42 are higher in amyloid-positive normal cognition (NC) individuals compared to mild cognitive impairment (MCI) and Alzheimer's disease (AD) and whether this relationship applies to neuropsychological assessments and hippocampal volume measured within the same year. All subjects were evaluated between June 2010 and February 2019. Brain amyloid positivity was defined as positron emission tomography-based standard uptake value ratio (SUVR) ≥1.08 for [18] F-florbetaben or 1.11 for [18]F-florbetapir, with higher SUVR indicating more brain amyloidosis. Analyses were adjusted for age, sex, education, APOE4, p-tau, t-tau, and centiloids levels. Higher soluble Aβ42 levels were observed in NC (864.00 pg/ml) than in MCI (768.60 pg/ml) or AD (617.46 pg/ml), with the relationship between NC, MCI, and AD maintained across all amyloid tertiles. In adjusted analysis, there was a larger absolute effect size of soluble Aβ42 than SUVR for NC (0.82 vs. 0.40) and MCI (0.60 vs. 0.26) versus AD. Each standard deviation increase in Aβ42 was associated with greater odds of NC than AD (adjusted odds ratio, 6.26; p < 0.001) or MCI (1.42; p = 0.006). Higher soluble Aβ42 levels were also associated with better neuropsychological function and larger hippocampal volume. Normal cognition and hippocampal volume are associated with preservation of high soluble Aβ42 levels despite increasing brain amyloidosis. Please refer to the Funding section at the end of the article.

18 September 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SKSeong Su Kang
Seong Su Kang
ZZZhentao Zhang
Zhentao Zhang
XLXia Liu
Xia Liu
FMFredric Manfredsson
Fredric Manfredsson
MBMatthew J. Benskey
Matthew J. Benskey
KYKeqiang Ye
Keqiang Ye
Significance: Alpha-synuclein plays an important role in the pathophysiology of Parkinson’s disease (PD), however the molecular mechanisms related to α-synuclein in neurodegeneration of PD remain unknown. We show that α-synuclein specifically inhibits BDNF/TrkB signaling, leading to dopaminergic neuronal death. The disruption of this interaction rescues TrkB signaling, preventing α-Syn–induced dopaminergic neuronal death and restoring motor functions. This study reveals the mechanism related to α-synuclein–induced neurotoxicity of PD via regulation of TrkB neurotrophic signaling.